Trials / No Longer Available
No Longer AvailableNCT02596997
Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Jazz Pharmaceuticals · Industry
- Sex
- All
- Age
- 2 Months
- Healthy volunteers
- —
Summary
Provide patients with serious AdV infection or disease access to treatment with BCV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brincidofovir | Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week |
Timeline
- First posted
- 2015-11-04
- Last updated
- 2022-03-14
Locations
46 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02596997. Inclusion in this directory is not an endorsement.